XNCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Xencor Inc (XNCR) is not a strong buy for a beginner investor with a long-term strategy at this time. Despite some positive technical indicators, the company's financial performance has significantly deteriorated, insiders are heavily selling, and the options data reflects a bearish sentiment. The lack of recent congress trading data and no strong Intellectia Proprietary Trading Signals further support a cautious approach.
The MACD is positive and expanding, indicating bullish momentum. The RSI is at 81.277, signaling overbought conditions. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are R1: 13.798 and R2: 14.605, with support at S1: 11.185 and S2: 10.378.
The success of a lymphoma therapy partnered with Incyte and its EU approval indicates potential growth opportunities. Barclays raised the price target to $27, reflecting optimism in the stock's future.
Revenue dropped 46.5% YoY in Q4 2025, and net income declined 87.56%. Insiders are heavily selling, with a 2127.20% increase in selling activity over the last month. Options data reflects bearish sentiment, and the stock is overbought based on RSI.
In Q4 2025, revenue dropped to $28.24 million, down 59.67% YoY. Net income fell to -$6.65 million, down 87.56% YoY. EPS dropped to -$0.09, down 87.67% YoY. Cash reserves declined to $610.8 million from $706.7 million in 2024.
Barclays maintains an Overweight rating and raised the price target to $27. BofA raised its price target to $20 but maintains a Neutral rating. Analysts highlight growth potential in biotech but express concerns about sustainability.
